The European Medicines Agency’s decision to host the Veterinary Medicines Info Day in a purely online format reflects both the evolving digital landscape and a cautious approach to stakeholder engagement. While the convenience of virtual attendance cannot be denied, this format inherently limits the depth of interaction and networking opportunities that are vital for fostering innovation and collaboration in veterinary medicine. Healthcare marketers and industry professionals should critically assess whether the EMA is leveraging this event to its fullest potential or simply ticking a regulatory communication box.
From a marketing perspective, the timing and structure of the event—spanning less than 24 hours—suggest a compressed agenda that may prioritize regulatory updates over strategic dialogue. For pharmaceutical and veterinary device companies, this is a double-edged sword. On one hand, concise sessions can streamline information dissemination; on the other, they risk alienating participants who seek comprehensive insights and actionable intelligence to inform product development and market positioning.
Moreover, the choice of Amsterdam as the nominal location, despite the event being broadcast online, indicates a symbolic nod to tradition rather than a commitment to accessibility or inclusivity. Industry stakeholders should question whether this approach truly aligns with the EMA’s broader mission to support innovation and public health. The lack of a hybrid or in-person component may also hinder smaller enterprises and startups that benefit from face-to-face interactions with regulators and peers.
In conclusion, while the EMA Veterinary Medicines Info Day 2026 serves as an important regulatory touchpoint, it falls short as a platform for dynamic industry engagement. Medical marketing professionals must advocate for more interactive, hybrid events that not only communicate compliance requirements but also stimulate collaboration, innovation, and market growth within the veterinary sector. The EMA’s approach could inadvertently stifle the very progress it aims to support.
Discover more from Medical Device Marketing Agency
Subscribe to get the latest posts sent to your email.